Sanofi has signed a definitive agreement to acquire the entire share capital of Kiadis Pharma in a deal valued at approximately 鈧�308m ($359m).
Under the agreement, Sanofi will offer 鈧�5.45 per share to Kiadis Pharma, a clinical-stage company developing cell-based immunotherapy products.
The acquisition will give Sanofi full control of next-generation natural killer (K-NK) cell platform and pipeline of cell-based cancer immune-therapeutics and infectious disease treatments.
The K-NK cell platform derives from allogeneic or 鈥榦ff-the-shelf’ NK cells from a healthy donor and these cells hunt for malignant cancer cells.
It can potentially make products rapidly and economically available for a broad range of indications.
Under the deal, Kiadis will develop NK cell-based medicines alone or with Sanofi鈥檚 existing platforms.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataFurthermore, the research, development and commercial expertise of Sanofi will be leveraged to advance Kiadis鈥� pipeline that includes NK cell-based medicines.
Sanofi Research & Development global head John Reed said:聽鈥淲e believe the Kiadis 鈥榦ff the shelf鈥� K-NK cell technology platform will have broad application against liquid and solid tumours, and create synergies with Sanofi鈥檚 emerging immuno-oncology pipeline, providing opportunities for us to pursue potential best-in-disease approaches.鈥�
On completion of the public offer, Sanofi will provide the resources and capabilities needed for boosting the development of Kiadis鈥� programmes.
Kiadis鈥� pipeline of NK cell therapies includes K-NK002, K-NK003 and KNK-ID-101.
KNK-ID-101 is a programme analysing the properties of K-NK cells and their suitability to fight SARS-CoV-2.聽It will also analyse whether the cells can be used as a post-exposure pre-emptive therapy for Covid-19 in high-risk patients.
The company anticipates initiating a Phase I / IIa trial evaluating the use of K-NK cells to treat covid-19 patients with government grant funding.
In July, the company licensed Kiadis鈥� pre-clinical K-NK004 programme for potential combination for multiple myeloma.
